Addex director reports 1.37M shares, options

Addex Therapeutics Ltd. director Raymond George Hill filed an initial ownership report showing his equity position in the company.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. director Raymond George Hill filed an initial ownership report showing his equity position in the company. He holds 1,365,532 shares of Common Stock listed on the SIX Swiss Exchange and a stock option over 273,107 shares of Common Stock.

The stock option has an exercise price of $0.0640 per share, becomes exercisable in equal monthly installments over a four-year period beginning on the exercisable date, and expires on January 7, 2034. The exercise price reflects conversion from Swiss francs at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Hill Raymond George

Role Director

Type	Security	Shares	Price	Value
holding	Stock-Option (Right to Buy)	--	--	--
holding	Common stock	--	--	--

Holdings After Transaction: Stock-Option (Right to Buy) — 273,107 contracts (Direct); Common stock — 1,365,532 shares (Direct)

Footnotes (3)

1. F1. Represents 1,365,532 shares of Common Stock listed on SIX Swiss Exchange.
2. F2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
3. F3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Raymond George Hill report owning in Addex Therapeutics (ADXN)?

Raymond George Hill reports owning 1,365,532 shares of Addex Therapeutics Common Stock listed on the SIX Swiss Exchange, plus a stock option over 273,107 underlying shares of Common Stock as disclosed in his initial ownership filing.

What are the key terms of Raymond Hill’s Addex Therapeutics (ADXN) stock options?

Hill holds a Stock-Option (Right to Buy) over 273,107 shares of Common Stock with a reported exercise price of $0.0640 per share, expiring on January 7, 2034, vesting in equal monthly installments over four years.

How do Raymond Hill’s Addex Therapeutics (ADXN) options vest?

The stock options vest in equal monthly installments over a four-year period beginning at the exercisable date. Each option gives the right to purchase one ADXN share listed on the SIX Swiss Exchange, according to the footnote disclosure.

How was the Addex Therapeutics (ADXN) option exercise price determined?

The reported exercise price of $0.0640 reflects conversion from Swiss francs to U.S. dollars at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026, based on the details provided in the footnotes.

Does the Form 3 for Addex Therapeutics (ADXN) show any recent insider buying or selling?

The Form 3 is an initial ownership report and lists Hill’s existing holdings in Common Stock and stock options. It does not show explicit buy or sell transactions; the entries are characterized as holdings with unknown transaction codes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 04:01 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hill Raymond George

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock	1,365,532(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-Option (Right to Buy)	01/08/2024(2)	01/07/2034	Common Stock	273,107	$0.064(3)	D

Explanation of Responses:

1. Represents 1,365,532 shares of Common Stock listed on SIX Swiss Exchange.

2. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

3. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Lenaic Nathanael Teyssedou by power of attorney	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)